Cytek CTO gifts 1,176,000 company shares

Cytek Biosciences, Inc. director and chief technology officer Yan Ming reported a bona fide gift of 1,176,000 shares of Common Stock.

Rhea-AI Filing Summary

Cytek Biosciences, Inc. director and chief technology officer Yan Ming reported a bona fide gift of 1,176,000 shares of Common Stock. The transfer carried a reported price of $0.00 per share, reflecting that it was a non-cash gift, not a market sale. After this disposition, Ming’s direct holdings are reported at 4,915,933 Common Stock shares, indicating he retains a substantial ownership position in the company.

Insights

Equity ownership and insider-transactions analyst

Large insider share gift with substantial holdings retained.

The filing shows Cytek Biosciences chief technology officer Yan Ming made a bona fide gift of 1,176,000 Common Stock shares at a stated price of $0.00 per share. Because this is coded as a gift, it is not an open-market sale and does not directly signal trading intent.

Following the gift, Ming’s direct position is reported at 4,915,933 shares, with no remaining derivative positions listed in this filing. The transaction reduces his stake but leaves a large continuing ownership interest, so it appears more like personal estate or wealth planning than a shift in view on the stock.

Insider Trade Summary

1,176,000 shares gifted

Gift 1 txn

Insider Yan Ming

Role CHIEF TECHNOLOGY OFFICER

Type	Security	Shares	Price	Value
Gift	Common Stock	1,176,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,915,933 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytek Biosciences (CTKB) report for Yan Ming?

Cytek Biosciences reported that chief technology officer Yan Ming made a bona fide gift of 1,176,000 shares of Common Stock. The Form 4 classifies the move as a non-derivative, non-cash transfer rather than an open-market sale or purchase.

Was the Cytek Biosciences (CTKB) insider transaction a share sale or a gift?

The transaction was a bona fide gift, not a sale. The Form 4 uses transaction code G and lists a price of $0.00 per share, indicating a non-cash transfer of 1,176,000 Common Stock shares by CTO and director Yan Ming.

How many Cytek Biosciences (CTKB) shares did Yan Ming transfer in this Form 4?

Yan Ming transferred 1,176,000 shares of Cytek Biosciences Common Stock. The filing records this as a non-derivative transaction coded as a bona fide gift, reflecting a disposition of shares without an associated market price or sale proceeds.

How many Cytek Biosciences (CTKB) shares does Yan Ming hold after the reported gift?

After the gift transaction, Yan Ming is reported to hold 4,915,933 shares of Cytek Biosciences Common Stock directly. This post-transaction balance shows he retains a substantial equity position despite gifting 1,176,000 shares in the reported Form 4 filing.

Does the Cytek Biosciences (CTKB) Form 4 show any option exercises or derivative trades?

The Form 4 does not report any derivative security transactions or option exercises. The derivative summary section is empty, and the only listed activity is the non-derivative bona fide gift of 1,176,000 Common Stock shares by chief technology officer Yan Ming.

What role does Yan Ming hold at Cytek Biosciences (CTKB) in this insider filing?

In the filing, Yan Ming is identified as both a director and an officer of Cytek Biosciences, serving as chief technology officer. The reported bona fide gift of 1,176,000 Common Stock shares reflects a change in his direct holdings, not his corporate role or responsibilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 06:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yan Ming

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNOLOGY OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		G		1,176,000	D	$0	4,915,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Valerie Barnett, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.